FOLD: Utang jangka cendhak perusahaan Amicus Therapeutics

Simbol lan logo merek Amicus Therapeutics (FOLD)

Short-term debt of up to one year on the GURU.Markets chart is supported by a stable staff of R&D experts retained through stock options. Amicus Therapeutics (FOLD) generates revenue through the supply of high-cost drugs for patients with Pompe and Fabry diseases via insurance funds. The value of 0.00 is established as the baseline, which, coupled with expanding Galafold sales and a strong pipeline, is driving the company toward net profit.

FOLD (Amicus Therapeutics Inc) riwayat Utang jangka cendhak perusahaan saka 04.07.2022 nganti 09.05.2026

FOLD (Amicus Corp): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
Bagan rega Amicus Therapeutics, Inc.|FOLD - Konsensus nilai wajar
- informasi kapitalisasi pasar:
Nilai pasar Amicus Therapeutics, Inc.|FOLD - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- data nilai buku modal saham:
Nilai Buku saben Saham Amicus Therapeutics|FOLD - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih amicusrx.com|FOLD - Nilai Agregat Aset
- data utang lan likuiditas:
Utang marang Ekuitas Amicus Therapeutics|FOLD - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Amicus Therapeutics|FOLD - Utang kumulatif perusahaan|Utang marang nilai buku Amicus Therapeutics, Inc.|FOLD - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Amicus Therapeutics|Rasio cepet amicusrx.com
- indikator pendapatan resik lan kelipatan nilai:
FOLD - Bathi resik perusahaan
Analisis dhasar perusahaan:Amicus Therapeutics, Inc. - FOLD
Produk seri Amicus Corp

An investment audit of Amicus Therapeutics (FOLD) requires an analysis of liabilities maturing within one year, which measure current liquidity and the risk of capital shortages. Monitoring the short-term debt portfolio on GURU.Markets allows for a comparison of the financial burden against the high stability of revenue from rare disease therapies, turning this indicator into a marker of business resilience in the face of debt payments.

Karo sapa Amicus Therapeutics saingan

ASND - Utang jangka cendhak perusahaan|Silihan lan utang jangka cendhak perusahaan MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Utang jangka cendhak perusahaan|Kewajiban jangka cendhak perusahaan Rhythm Corp|AKRO (Akero Therapeutics) - Utang jangka cendhak perusahaan|Utang jangka cendhak perusahaan metsera.com|Kewajiban jangka cendhak perusahaan MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Silihan lan utang jangka cendhak perusahaan|Utang jangka cendhak perusahaan NewAmsterdam Pharma N.V. NAMS|SLNO - Kewajiban jangka cendhak perusahaan|89bio, Inc. - Utang jangka cendhak perusahaan|Utang jangka cendhak agios.com|GPCR (Structure Therapeutics Inc.) - Kewajiban jangka cendhak perusahaan|MDXG: Gedhene kewajiban jangka cendhak|RZLT (Rezolute Corp) - Utang jangka cendhak perusahaan|Utang jangka cendhak perusahaan Lexicon Corp|Utang jangka cendhak perusahaan MBX|Utang jangka cendhak perusahaan ALT (altimmune.com)|Utang jangka cendhak perusahaan Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Utang jangka cendhak|BIOA - Utang jangka cendhak perusahaan|BMEA: Utang jangka cendhak perusahaan|QNCX: Utang jangka cendhak perusahaan|GUTS - Gunggunge utang jangka cendhak|Utang jangka cendhak perusahaan vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Gunggunge utang jangka cendhak|Utang jangka cendhak perusahaan Pluri Inc. (PLUR)|Kewajiban jangka cendhak perusahaan synlogictx.com SYBX|Utang jangka cendhak perusahaan LPCN (Lipocine Inc.)|Utang jangka cendhak perusahaan Matinas BioPharma Holdings, Inc. MTNB|SPRB - Utang jangka cendhak perusahaan|Galecto Inc (GLTO) - Kewajiban jangka cendhak perusahaan|CTCX: Utang jangka cendhak perusahaan|LUMO - Gunggunge utang jangka cendhak|ONVO (Organovo Holdings, Inc.) - Utang jangka cendhak perusahaan|Kewajiban jangka cendhak perusahaan radiuspharm.com (RDUS)